NCT06100497View on ClinicalTrials.gov

Efficacy and Safety of PD-1 Plus Chemotherapy in Poorly Differentiated Locally Advanced (LA) HNSCC

PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

October 1, 2023

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2028

Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
DRUG

Pembrolizumab

Mainly used for neoadjuvant treatment and subsequent adjuvant or maintenance treatment

DRUG

Cisplatin

Mainly used for neoadjuvant treatment and concurrent chemoradiotherapy

DRUG

Paclitaxel-albumin

Mainly used for neoadjuvant treatment

Trial Locations (1)

10000

RECRUITING

Beijing Tongren Hospital Affiliated to Capital Medical University, Beijing

All Listed Sponsors
lead

Beijing Tongren Hospital

OTHER